Therapex.co.,ltd.

 

 

Therapex.co.,ltd.

File:테라펙스 로고.jpg 테라펙스 본사.jpg Therapex.co.,ltd. C.I
File:테라펙스 본사.jpg Therapex HQ Seoul Songpagu Munjeongdong
Native name	주식회사 테라펙스
Formerly	Interpark bioconvergence.co.,ltd.
ISIN	🆔
Industry	Medical, pharmaceutical research and development
Founded 📆	31 July 2020 (2020-07-31) in Seoul, South Korea
Founder 👔
Headquarters 🏙️	3F, Jeongui-ro 7-gil, Songpa-gu, Seoul , Republic of Korea
Area served 🗺️
Key people	Lee Koo (CEO), Kiwon Suh (CFO), Kwangwoo Chun (Drug discovery), Myoungki Baek (Translational research), Jiyeon Park (Clinical development)
Owner	Gradiant (51%), Imarket Korea (49%)
Members
Number of employees	30 (2023)
Parent	Gradiant, Imarket Korea
Subsidiaries	Gradiant, Imarket Korea, Allen care, Guardian, Ilogistics, Qu bridge, Gradiant bioconvergence, Imtechnology, KAOS
🌐 Website	HomePage / Blog / LinkedIn / JobPlanet
📇 Address
📞 telephone

Overview

Therapex.co.,ltd.(Korean:테라펙스) was founded in July 2020, starting from Interpark bioconvergence research center in 2017. It has changed its name from Interpark bioconvergence to Therapex after the spin off from Gradiant bioconvergence in 2022.

History

2022

Feb : Joint research agreement with Elgen Therapeutics on developing PROTAC agents

Apr : Completing the spinoff of Organoid Division

Apr : Changing the corporate name to Therapex

May : HQ office / biology laboratory expansion

2021

Mar : Appointing Dr. Koo Lee as CEO

Aug : Moving HQ and R&D center to Songpa area with expanded capacity

Sep : Embarking on build-up of new drug R&D pipeline

2020

Jul : Founded Interpark Bioconvergence Corp.

Aug : Acquisition of Interpark Bio Convergence Research Institute assets

Aug : Joint research agreement with Yonsei University Severance Biomedical Science Institute on developing new drugs for lung cancer patients

2017

Apr : Founded Interpark bioconvergence research center

R&D

New drug discovery platform Ⅰ

Molecular design

- Efficient in-silico design of anti-cancer agents utilizing X-ray crystal structure of target proteins and molecular docking

- Creative construction of molecular agents with high activity and selectivity based on the insight into the binding modes of existing drugs

Target Analysis

- Building in-house database using crystal structures

- Establishing unique strategies based on R&D outcomes

Design

- Effective drug design based on in-house expertise

- Simulation via molecular dockings

Synthesis

- Analysis of docking and crystal structures

- Synthesis of strictly selected compounds

Bioassay

- Biochemical assay

- Cell-based assay

- In vivo efficacy study

Discovery of orally bioavailable PROTACs

Many ongoing studies on PROTAC show difficulty in oral absorptions

- “The real bottleneck is making PROTACs orally bioavailable. They have a higher molecular weight (0.7–1.1 kDa), more hydrogen bond donors and a larger polar surface area than typical small molecules, all factors that work against gut

- Therapex has strong expertise on enhancing the oral absorption of compounds with MW of 500~900 that violate the Rule of 5.

Facility

In-house cutting-edge system to expedite the R&D progress in molecular design & synthesis, bioassay, DMPK, in vivo efficacy study, etc.

Synthesis Laboratory

Fume hood, low temperature reactor, MPLC, HPLC, LC/MS, LC/MS/MS, NMR, etc.

Biology Laboratory

CO2 Incubator, bio safety cabinet, fluorescence microscope, multi-plate reader, Chemi-doc, deep freezer, etc.

Laboratory Animal Facility

Animal Breeding Area (Mouse Breeding Room, Rat Breeding Room), Animal Testing Area, Wash Room, etc.

Welfare

Salary

The average salary seems to be higher than that of other industries as Therapex falls under the biopharmaceutical industry category. Therapex can get financial support from its mother company Gradiant whereas many bio venture companies should finance themselves. The average salary seems to be higher than that of other biopharmaceutical companies thanks to the support from mother company.

Welfare system

Welfare system seems to be pretty good as Therapex is a subsidiary of a big conglomerate group.

Medical checkup

Meal benefit

children's tuition support

self-enrichment, medical, travel support at actual expense

Group accident insurance

Family event

Overtime pays for meal and transportation expenses

Flexible commute time

Incentive bonus & stock option

Holiday gifts

Corporate card

Parking spot and expense support

Snack bar

Miscellaneous

Job satisfaction

It seems to be high. The current job satisfaction score is 3.3 at Jobplanet.

Related Media

2023

- 김성민 기자, 테라펙스, 4세대 EGFR TKI “6월 韓·美 1상 IND 제출”, 바이오스펙테이터, 2023.04.20
- TRX-221, fourth-generation EGFR inhibitor with significant antitumor activity in EGFR-mutant NSCLC, BioWorld, 2023.04.19
- Han-soo Lee, Therapex unveils preclinical results of novel NSCLC treatment at AACR, KBR, 2023.04.19
- 김윤미 기자, 세계 암 전문가들에게 주목받은 테라펙스 TRX-221, 청년의사, 2023.04.19
- 김윤미 기자, 토종 4세대 EGFR TKI 등장 기대↑…테라펙스,임상 시동, 청년의사, 2023.04.14
- 명순영 기자, 테라펙스,4세대 비소세포폐암 치료제 후보물질 TRX-221 임상자문위원회 열어, 매경이코노미, 2023.03.23
- 김성민 기자, 테라펙스,4세대 EGFRTKI AACR 공개... 올해 임상, 바이오스펙테이터, 2023.02.10

2022

- 명순영 기자, 테라펙스, 우시앱텍과 신규항암제 개발 MOU 체결, 매경이코노미, 2022.10.06
- 명순영 기자, 인터파크바이오,테라펙스로 사명 바꿔 재출발, 매경이코노미, 2022.04.04
- 김상일 기자, 인터파크바이오컨버전스 표적단백질분해 항암 신약 개발 나선다, 의학신문, 2022.02.15
- 명순영 기자, 인터파크,전자상거래 이어 바이오 승부수 띄운다, 매경이코노미, 2022.01.10

2021

- 명순영 기자, 인터파크바이오,항암제 개발 속도 낸다, 매경이코노미, 2021.09.08
- 이아영 기자, 이구 인터파크바이오 부사장,대표직 맡는다, 더벨, 2021.03.18
- 최진호 기자, 인터파크바이오,신약 연구개발 부사장에 이구 박사 선임, 뉴스락, 2021.01.15

분류:South Korean brands 분류:Companies based in Seoul 분류:Companies of South Korea 분류:Health care companies 분류:Pharmaceutical companies 분류:Pharmaceutical companies of South Korea 분류:Biotechnology companies of South Korea

This article "Therapex" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Therapex. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

---